We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genuit Group Plc | LSE:GEN | London | Ordinary Share | GB00BKRC5K31 | ORD GBP0.001 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.50 | -0.12% | 401.00 | 859,401 | 16:35:08 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 400.50 | 401.50 | 403.00 | 398.50 | 401.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Plastics Pipe | 586.5M | 38.5M | 0.1545 | 25.99 | 1B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:08 | O | 12 | 400.50 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/12/2024 | 17:25 | UK RNS | Genuit Group PLC Holding(s) in Company |
| 25/11/2024 | 13:01 | UK RNS | Genuit Group PLC Director/PDMR Shareholding |
| 19/11/2024 | 17:55 | UK RNS | Genuit Group PLC Holding(s) in Company |
| 19/11/2024 | 09:43 | ALNC |  Genuit Group sees revenue decline amid subdued market conditions |
| 19/11/2024 | 07:00 | UK RNS | Genuit Group PLC Trading Update |
| 15/11/2024 | 15:10 | UK RNS | Genuit Group PLC Holding(s) in Company |
| 01/11/2024 | 13:37 | UK RNS | Genuit Group PLC Block listing Interim Review |
| 31/10/2024 | 13:14 | UK RNS | Genuit Group PLC Holding(s) in Company |
| 11/10/2024 | 11:23 | UK RNS | Genuit Group PLC Holding(s) in Company |
| 07/10/2024 | 15:05 | UK RNS | Genuit Group PLC Holding(s) in Company |
Genuit (GEN) Share Charts1 Year Genuit Chart |
|
1 Month Genuit Chart |
Intraday Genuit Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 27/9/2024 | 17:24 | Genuit Group | 57 |
| 19/11/2006 | 19:49 | GEN - SILLY PRICE | 500 |
| 26/8/2004 | 04:32 | Watching closely | - |
| 07/8/2003 | 13:33 | Anyone here invested in Generics? | 3 |
| 10/4/2002 | 16:16 | Further gloom for Generics UK | 4 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 15/12/2024 08:20 by Genuit Daily Update Genuit Group Plc is listed in the Plastics Pipe sector of the London Stock Exchange with ticker GEN. The last closing price for Genuit was 401.50p.Genuit currently has 249,169,872 shares in issue. The market capitalisation of Genuit is £1,000,417,036. Genuit has a price to earnings ratio (PE ratio) of 25.99. This morning GEN shares opened at 401.50p |
Posted at 16/8/2022 13:40 by km18 Genuit posted Interims for the 6 months ended June 30th 2022 this morning. The Group performed reasonably in the HY period with revenues up 7.6% to £318m, PBT down 2.7% to £32.9m and EPS up 27.6% to 10.1p. According to Joe Vorih, CEO, “Agile pricing leadership offset inflationary pressures, and the effect of selective business decisions helped to increase our margins. While mindful of the macroeconomic pressures, we have good momentum as we enter the second half, and the Group anticipates meeting full year expectations.” These are for high single digit revenue growth and widening margins. However, consensus market estimates for FY22 EPS at 33.7p look too aggressive. Valuation is also a little unhelpful with forward PE ratio at 12.4x in the bottom quartile for the sector. Share price is also still in a 12-month correction for now. GEN is a share to monitor for now......from WealthOracle |
Posted at 18/2/2022 13:37 by km18 ...from last year...Company overview: Genuit Group is actually the new name of Polypipe Group plc. They provide sustainable solutions for water, climate and ventilation management. Sustainability is at the core of the firm’s strategy, driven by constant innovations. Genuit benefits from the active plans of governments across the globe to achieve net zero strategies and promote ESG activities and foresees geographic reach to be a major driver of growth for the group in the long term. Blended approach for growth, with several acquisitions and continuous Capex seems to be working for the company in the long run, as both revenues and EPS have been growing steadily over the past 6 years, with the sole exception the catharsis of 2020. Fundamentally the company is also supported by a solid history of debt retirement and cash generation. the half-year report sounds very promising. The group revenue was 32.5% above the 2019 figure (yes, that is a 3rd above the covid free year), driven by a significant raise in residential business at £183.8m (64% growth yoy lfl basis). The sole red flag on the report comes in the face of pressured margins, coming from the rising input costs. This has been balanced very nicely by 8% increase in prices for final customers, which proves the company’s brand recognition. The labour supply issues several sectors are experiencing seems to be fading at Genuit, but we suggest keeping your eyes open for September for further guidance on the direction of the “pingdemic&rdq |
Posted at 16/11/2021 15:43 by scooper72 Looks like Aberdeen Standard Investments who hold 10.96 percent have cut their holding by about 10 percent and sold 2.3M shares last month. And I guess there must be others with large holding taking some profits. I'm now down an annoying 14 percent on my current holding in my SIPP having sold out previously at 688p with my original larger holding in my ISA. But thinking it is a bit late to comfortably take the £300 loss without worrying about doubly kicking myself if the price recovers. Today's drop seems hard to understand when considering the results out this morning looked ok |
Posted at 16/11/2021 10:29 by dope007 Input costs are definitely not past their peak. Additionally the industry is seeing further raw material shortage issues.Order books are full but at some point these horrendous input price rises are going to lead to reducing orders. However Genuit are in a better place than the window boys with less reliance on the home replacement mkt were at some point a home owner is going to say nope, not paying that... |
Posted at 16/11/2021 08:32 by scooper72 Do you see these factors averaging out in terms of when they announce their profits or do you see the share price pulling back further on results whenever they come out. Ok kicking myself for going back in a bit early and just wondering where fair value is currently. |
Posted at 13/10/2021 12:12 by dope007 Like the rest of our industry 2 dynamics are at play1) Raw mat massive price hikes and ongoing/rolling shortages 2) High demand so selling everything they can produce even at higher prices |
Posted at 19/8/2021 09:49 by philanderer Yesterday's Deutsche note..(Sharecast News) - Analysts at Deutsche Bank raised their target price on plastic piping manufacturer Genuit from 653.0p to 708.0p on Wednesday, citing the group's "strong" first-half performance Deutsche Bank pointed to Genuit's adjusted interim operating profit of £48.6m, eclipsing its 2019 first-half performance by roughly 24% as it primary reason for the upgrade but also noted that the company appeared to be continuing to trade well, prompting a rise in management's expectations for the full year. "We raise our 2021-2023E operating profit forecasts by 4-7% and our target price by circa 8%," said the German bank, which also reiterated its 'buy' rating on the stock. "The company remains a strong performer, with recent acquisitions operating at or above expectations (three in February alone indicative of a team that does not let the grass grow under its feet)." |
Posted at 18/8/2021 13:08 by philanderer Keyno, it seems to be bouncing back. Maybe helped by this?Genuit Group: Deutsche Bank keeps at buy and raises target price from 653.0p to 708.0p. |
Posted at 24/5/2021 17:40 by philanderer Genuit Group: Berenberg reiterates hold with a target price of 630p. |
Posted at 30/8/2005 07:19 by ariane Interim ResultsRNS Number:5593Q Generics Group AG 30 August 2005 30 August 2005 THE GENERICS GROUP AG ('GENERICS') INTERIM RESULTS 2005 Generics, a leading integrated technology consulting, development and investment organisation, today announces its results for the six months to 30 June 2005. Highlights: * Turnover increased by 28% to #10.7m (H1 2004: #8.3m) * Consulting and IP exploitation activities reported operating profit of #0.3m (H1 2004 loss of #0.1m) while increasing fee income by 34% * Operating loss for the Group of #0.9m (H1 2004 loss of #2.1m) after expensed costs of spinouts of #0.6m * Portfolio BVCA valuation of #12.5m (Q1 2005: #11.9m) * Cash balance of #3.6m (Q4 2004: #5.1m) before proceeds of #1.05m from the disposal of Imerge Ltd * Generics' spinout CMR Fuel Cells Ltd received the 2005 Carbon Trust award as Innovator of the year and in addition was a winner of the Individual and Small Business of the Year category * Successful completions of #4m financing by Sphere Medical Holding Ltd, originally Generics' medical device joint venture with Siemens, and #2.3m financing by CMR Fuel Cells Ltd * Launch of SGAI Tech Ltd, Scientific Generics' Hong Kong based joint venture * Adjusted losses per share of 0.5 pence (2004 loss of 1.0 pence) * Net assets per share of 8.7p per share (H1 2004: 9.4p) before taking into account the BVCA portfolio valuation uplift equivalent to 3.5p per share (H1 2004: 3.0p) On 11 August 2005 Generics announced that it had completed the sale of its shareholding in Imerge Limited. The consideration included a cash payment of #1.05m, and future incentive payments dependent upon performance. The BVCA valuation for Generics' share of Imerge at Q1 2005 was #1.3m. Johan Bjorklund, Generics' Chairman, commented: "I am pleased with both the development of the group during the first six months and the progress in the consulting and IP exploitation activities in particular. Our core technology development and consulting activity grew significantly, increasing fee income by 34% year-on-year whilst achieving a good and increasing profitability. SGAI Tech, our Hong Kong based joint venture, is performing ahead of forecast, adding new clients to its initial customer, Hornby plc. Income from licensing and royalty activities will improve with the next AutosheathTM milestone payment of $0.5m expected in the second half. While Q3 is likely to see a moderate seasonal reduction in revenue and sales run-rate, the order book and sales processes are now strong enough to sustain the ongoing growth in the technology consulting and IP business. Within our venturing activity during the first half we have received industry accolades for our spinout companies, CMR Fuel Cells Ltd and Sphere Medical Holding Ltd, both of which have been successfully financed in the year to date. Various funding, IPO and disposal opportunities continue to be developed across the portfolio. The prospects for CMR and Sphere, in particular, are strong." Enquiries: The Generics Group AG (44) 1223 875200 Martin Frost www.genericsgroup.co Simon Davey |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
